In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Approves Continued Use Of Strattera For AD/HD Patients Over 18

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare June 15 notified Eli Lilly's Japan subsidiary it expanded labeling for Strattera (atomoxetine), allowing the drug to be used continuously for patients over 18 years. Currently, Strattera is indicated for attention-deficit hyperactivity disorder for patients aged 6 to 18. However, the change only applies to patients who have started taking the drug before the age of 18 and need to continue the treatment. Eli Lilly is conducting a Phase III trial of Strattera on adult patients. Many AD/HD patients in Japan have expressed a desire to continue the medication even after they turn 18. (Click here for more - Japanese language)

You may also be interested in...



GNC In Rough Seas From COVID-19 Pandemic; Vitamin Shoppe Safe In Port Under New Owner

GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.

QUOTED. 7 April 2020. Surendar Magar.

California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.

EMA's Decision On Ranitidine Remaining Available Could Come At End Of April

Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.

UsernamePublicRestriction

Register

SC075094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel